Literature DB >> 30209953

Bi-plane and single plane angiography: a study to compare contrast usage and radiation doses for adult cardiac patients in diagnostic studies.

Keith Smith1, James Crowhurst1, Darren Walters2, Deborah Starkey3.   

Abstract

OBJECTIVE: : This study compares the performance of bi-plane coronary angiography against single plane angiography in terms of the volume of contrast used (ml) and the total dose-area product (DAP) (μGym2) to the patient measured directly via flat panel detectors.
METHODS: : A total of 5176 adult diagnostic cardiac angiograms from a hospital in Brisbane, Australia were retrospectively studied. Patients with aortograms, iliac or femoral artery imaging, and stenting or graft interventions were excluded. Student's t-tests were used to compare means, and confounding variables were compared using multivariate regression. This quantified the effects of bi-plane system use holding constant other factors (e.g.) body mass index (BMI), age, room, sex, number of digital acquisitions and fluoro time.
RESULTS: : Bi-plane imaging had an average difference in mean contrast use of -15.1 ml [15.5% 95% confidence interval (CI) (-13.2, -17.0) p<0.001], multivariate regression demonstrated a -27.0 ml reduction in contrast use [28% 95% CI (-29.0, -24.83) p<0.0001] when the significant effects of fluoro time, number of digital acquisitions, BMI and sex were held constant. Bi-plane imaging had an average difference in mean DAP of + 887.1 μGym2 [23% 95% CI (+1110.7, +663.4) p < 0.001], whilst multivariate regression found a +628.3 Gym2 increase in DAP [16% 95% CI (+467.5, +789.3) p<0.001] when the significant effects of fluoro time, number of digital acquisitions, BMI and sex were held constant.
CONCLUSION: : These results demonstrate that bi-plane imaging uses less contrast media than single-plane imaging for coronary angiography at the expense of more radiation. Bi-plane imaging may be preferable in patients with renal impairment, however single plane imaging may be preferable in those without renal impairment. ADVANCES IN KNOWLEDGE:: This is a large cohort and statistically comprehensive study comparing bi-plane and single plane coronary angiography. Other studies 4, 5, 6, 12 have used Student's t-tests to measure the difference between means, however this provides no causative information on the differences found. This study provides a view of the causative impact of bi-plane usage on DAP and contrast use via multivariate regression modelling.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30209953      PMCID: PMC6435067          DOI: 10.1259/bjr.20180367

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  3 in total

1.  Agreement between single plane and biplane derived angiographic fractional flow reserve in patients with intermediate coronary artery stenosis.

Authors:  Jiro Ando; Katharina Otani; Thomas Redel; Shun Minatsuki; Hironobu Kikuchi; Satoshi Kodera; Issei Komuro
Journal:  Heart Vessels       Date:  2021-11-11       Impact factor: 2.037

2.  Effect of Different Anthropometric Body Indexes on Radiation Exposure in Patients Undergoing Cardiac Catheterisation and Percutaneous Coronary Intervention.

Authors:  Youlin Koh; Sara Vogrin; Samer Noaman; Simon Lam; Raymond Pham; Andrew Clark; Leah Biffin; Laura B Hanson; Jason E Bloom; Dion Stub; Angela L Brennan; Christopher Reid; Diem T Dinh; Jeffrey Lefkovits; Nicholas Cox; William Chan
Journal:  Tomography       Date:  2022-09-11

3.  National Cardiovascular Data Registry-Acute Kidney Injury (NCDR) vs. Mehran risk models for prediction of contrast-induced nephropathy and need for dialysis after coronary angiography in a German patient cohort.

Authors:  Claudio Parco; Maximilian Brockmeyer; Lucin Kosejian; Julia Quade; Jennifer Tröstler; Selina Bader; Yingfeng Lin; Alexander Sokolowski; Alexander Hoss; Yvonne Heinen; Volker Schulze; Andrea Icks; Christian Jung; Malte Kelm; Georg Wolff
Journal:  J Nephrol       Date:  2021-08-07       Impact factor: 3.902

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.